PolyPid (PYPD)
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid enc...
- Open
- 5.130
- High
- 5.145
- Low
- 4.985
- Prev. Close
- 5.120
- Volume
- 63.72K
- Turnover
- 321.94K
- Avg Price
- 5.052
- Bid/Ask Ratio
- --
- Amplitude
- 3.13%
- 52wk High
- 5.730
- Volume Ratio
- 0.06
- Turnover Ratio
- 0.55%
PolyPid Analyst Rating
View moreForecast & Rating
Aug 14, 2026Price forecast
$11.75131.76%
Forecast & RatingStrong buy
4analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Motley Fool · Aug 19 at 10:11 AM
PolyPid (PYPD) Q2 2026 Earnings Call Transcript
- TradingKey · Aug 14 at 03:36 AM
PolyPid (PYPD) Q2 2026 Earnings Call: D-PLEX100 Priority Review and Azurity Deal
- Market Beat · Aug 12 at 12:11 PM
PolyPid (NASDAQ:PYPD) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS
- Quartr · Aug 12 at 06:40 AM
PYPD: FDA accepted NDA for D-PLEX 100; $30M milestone secured, cash runway projected into 2028
- PUBT · Aug 12 at 06:32 AM
PolyPid Q2 FY26 net loss narrows 22% to $7.8 million
- Unusual Whales · Aug 12 at 06:32 AM
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
